$0.9155
-0.00540-0.59%
At close: -
$0.9200
0.004500.49%
After Hours: Dec 20, 5:43 PM EDT
Comments
Loading...
Seres Therapeutics (MCRB) Forecast
NewsEarningsSeres Therapeutics (MCRB) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestSeres Therapeutics (NASDAQ:MCRB) Stock Quotes, Forecast and News Summary
Seres Therapeutics Stock (NASDAQ: MCRB) stock price, news, charts, stock research, profile.
Compare
EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS better than industry
FAQ
How do I buy Seres Therapeutics (MCRB) stock?
You can purchase shares of Seres Therapeutics (NASDAQ:MCRB) through any online brokerage.
Who are Seres Therapeutics (MCRB) competitors?
Other companies in Seres Therapeutics’s space includes: Zura Bio (NASDAQ:ZURA), Aligos Therapeutics (NASDAQ:ALGS), Adaptimmune Therapeutics (NASDAQ:ADAP), Tevogen Bio Holdings (NASDAQ:TVGN) and Kyverna Therapeutics (NASDAQ:KYTX).
What is the forecast, or price target, for Seres Therapeutics (MCRB) stock?
Seres Therapeutics has a consensus price target of $9.75.
What is the current price for Seres Therapeutics (MCRB)?
The stock price for Seres Therapeutics (NASDAQ: MCRB) is $0.92 last updated December 20, 2024 at 5:43 PM EST.
Does Seres Therapeutics (MCRB) pay a dividend?
There are no upcoming dividends for Seres Therapeutics.
When is Seres Therapeutics (NASDAQ:MCRB) reporting earnings?
Seres Therapeutics’s Q4 earnings are confirmed for Tuesday, March 4, 2025.
Is Seres Therapeutics (MCRB) going to split?
There is no upcoming split for Seres Therapeutics.
What sector and industry does Seres Therapeutics (MCRB) operate in?
Seres Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.